A5073164087- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
- Cancer Research and Treatments
- RNA modifications and cancer
- Immune cells in cancer
- Immune Cell Function and Interaction
- interferon and immune responses
- Cancer Cells and Metastasis
- Immunotherapy and Immune Responses
- Cytomegalovirus and herpesvirus research
- Herpesvirus Infections and Treatments
- Phagocytosis and Immune Regulation
- Hippo pathway signaling and YAP/TAZ
- Fungal Infections and Studies
- T-cell and B-cell Immunology
- Cancer-related molecular mechanisms research
- Single-cell and spatial transcriptomics
- MicroRNA in disease regulation
- Pneumocystis jirovecii pneumonia detection and treatment
- Autoimmune Neurological Disorders and Treatments
- Antifungal resistance and susceptibility
- Lung Cancer Research Studies
Seoul National University Hospital
2020-2025
Seoul National University
2020-2025
Abstract Background We investigated the role of tumor cell-intrinsic PD-L1 signaling in epithelial−mesenchymal transition (EMT) non-small-cell lung cancer (NSCLC) and EMT as a predictive biomarker for immune checkpoint inhibitor (ICI) therapy. Methods PD-L1-overexpressing or PD-L1-knockdown NSCLC cells underwent RNA-seq phenotype assessment. Mouse LLC were injected into nude mice. Two cohorts patients with undergoing ICI therapy analyzed. Results showed that pathways enriched PD-L1-high...
The importance of mitochondrial function in macrophages is well established. Alveolar (AMs), the tissue-resident (TRMs) lung, are particularly dependent on mitochondria-driven oxidative phosphorylation (OXPHOS) to support their functions and maintain homeostasis. However, specific genes pathways that regulate OXPHOS AMs remain unclear. In this study, we investigated role CR6-interacting factor 1 (CRIF1), a regulator, as key specifically modulates metabolic fitness maintenance AMs. Using...
Some patients with non-small-cell lung cancer (NSCLC) benefit from immune checkpoint inhibitors (ICIs) despite programmed death-ligand 1 (PD-L1) expression. To address the mechanism of ICI resistance in PD-L1-positive NSCLC, we investigated role tumor-cell-intrinsic function PD-L1 interleukin (IL)-6-mediated immunosuppression. Cohorts NSCLC treated and public datasets were analyzed. PD-L1-overexpressing PD-L1-knockdown cells submitted to RNA-seq, vitro analyses, chromatin...
Abstract Type-2 innate lymphoid cells (ILC2s) exhibit dual functions in cancer, both promoting and inhibiting tumor growth by regulating anti-tumor immune responses. Elucidation of the precise mechanisms which ILCs regulate adaptive responses could support development improved immunotherapeutic approaches. Here, we revealed that ILC2s possess capacity to internalize, process, present exogenous antigen on major histocompatibility complex class I (MHC I) molecules, along with costimulatory...
Recently identified human FOXP3
Abstract The expression of PD-L1 on tumor cells (TC) is used as an immunotherapy biomarker in lung cancer, but heterogeneous intratumoral often observed. To better understand heterogeneity the cancer microenvironment, we performed proteomic and whole-transcriptomic digital spatial profiling analyses TCs immune (IC) spatially matched areas based status microenvironment. We validated our findings using IHC, data from Cancer Genome Atlas, cohorts. ICs with high showed more features, indicative...
<div>Abstract<p>The expression of PD-L1 on tumor cells (TC) is used as an immunotherapy biomarker in lung cancer, but heterogeneous intratumoral often observed. To better understand heterogeneity the cancer microenvironment, we performed proteomic and whole-transcriptomic digital spatial profiling analyses TCs immune (IC) spatially matched areas based status microenvironment. We validated our findings using IHC, data from The Cancer Genome Atlas, cohorts. ICs with high showed...
<p>The difference in immune factors across metabolic subtypes.</p>
<p>The characteristics of immune cells according to tumor PD-L1 expression in deficient microenvironment.</p>
<p>Survival analysis according to subtype of NSCLC in ICI cohort</p>
<p>Flow chart for patient selection and inclusion exclusion criteria DSP analysis of this study</p>
<p>Principal Component Analysis (PCA) and the distribution of tumor PD-L1 expression in total or per group using DSP analysis.</p>
<p>The characteristics of tumor cells based on the degree immune cell infiltration and PD-L1 expression in microenvironment.</p>